Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 790-791, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cerutti, A.
Right arrow Articles by Perazzi, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cerutti, A.
Right arrow Articles by Perazzi, C.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2002;48:790-791.)
© 2002 American Association for Clinical Chemistry, Inc.

Technical Briefs

Comparison of Cardiac Troponin I in Serum and Heparin Plasma with the Dimension RxL Assay

Alberto Cerutti1a, Leonora Corsini1, Roberto Finotto1 and Carlo Perazzi1

1 Clinical Laboratory, S. Biagio Hospital, 28845 Domodossola, Italy

aauthor for correspondence: fax 39-0324-4961247, e-mail labanalisidomo@asl14.it.

Cardiac troponin [I (cTnI) and T (cTnT)] assays in blood have rapidly become alternatives to older methods for detecting myocardial damage (1)(2). Furthermore, the recently redefined criteria for myocardial infarction that are used to classify patients with acute coronary syndrome have been established on the basis of increased serum/plasma cTnI or cTnT (3). The National Academy of Clinical Biochemistry has recommended the use of plasma rather than serum as the specimen of choice (4), citing improved turnaround times and potentially avoiding incomplete serum separation that may influence some methods to produce falsely increased results (5). However, some studies have shown lower cTnI and cTnT concentrations in plasma than in serum (6)(7). Because heparin effects vary among different analytical methods, we performed a study to evaluate cTnI concentrations in plasma and serum specimens assayed on the Dimension RxL (Dade Behring).

We evaluated assay imprecision using lyophilized control sera with three different concentrations of cTnI (0.57, 5, and 15 µg/L) that were analyzed 10 times in one analytical run for the determination of within-run imprecision and 24 times on 24 different days for the determination of between-run imprecision. Our results confirmed the manufacturer’s claims that within- and between-run imprecisions (CVs) were 2.8–3.9% and 2.9–4.1%, respectively. . . . [Full Text of this Article]


References




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
R. M. Dorizzi, M. Caputo, A. Ferrari, L. Lippa, and P. Rizzotti
Comparison of Serum and Heparin-Plasma Samples in Different Generations of Dimension Troponin I Assay
Clin. Chem., December 1, 2002; 48(12): 2294 - 2296.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.